Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition

Immunotherapy for ovarian cancer is an area of intense investigation since the majority of women with relapsed disease develop resistance to conventional cytotoxic therapy. The paucity of safe and validated target antigens has limited the development of clinically relevant antibody-based immunothera...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Front Immunol
Main Authors: Yeku, Oladapo O., Rao, Thapi Dharma, Laster, Ian, Kononenko, Artem, Purdon, Terence J., Wang, Pei, Cui, Ziyou, Liu, Hong, Brentjens, Renier J., Spriggs, David
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2021
נושאים:
Immunology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8079980/
https://ncbi.nlm.nih.gov/pubmed/33936101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.663379
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים